In a note, analysts Richard B. Silver and Ann Trimble in New York reiterated the Jerusalem drugmaker outperform with a $65 target price. "Teva remains our favorite name in the generic space -- well-poised to exceed modest expectations implied by current valuation" they wrote. "With anticipation of Teva's updated long-term strategic plan expected on Jan. 5 and likely improving quarterly earnings to finish fiscal 2009 on a high note, we expect the stock to resume its long-term track record of outperformance, particularly as investors begin to focus on fiscal 2010's projected growth acceleration and likely upwardly revised 2012 forecast on Jan. 5." Full Article at MarketWatch